Tech Innovations in Ophthalmology, the Latest on Online Eye Exams and Prescriptions | AAO 2023

A panel of speakers demonstrated different ways technology and artificial intelligence (AI) could greatly expand access to glaucoma care.

ChatGPT bested Google in a blinded comparison of their answers to common oculoplastic questions.

Changes have been proposed to the quality payment program that could have ups and downs, but not, perhaps for some, until 2029.

A new statistical models shed light on why some patients can extend the dosing interval with Eylea (aflibercept) from 8 weeks to as long as 20 weeks for neovascular age-related macular degeneration (nAMD) or diabetic macular edema (DME).

Subgroup analyses of the PHOTON trial show visual acuity gains across subgroups by race, baseline visual acuity and retina thickness.

Clinical and other trials for GLP-1 therapies have found an association between these drugs and diabetic retinopathy complications in patients. But this could be an early worsening of disease unrelated to treatment.